Radiation Therapy for Liver Cancer

 

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells. Radiation therapy is used after surgery to help prevent the liver cancer from coming back (recurring) or to help treat symptoms. It can be given internally or externally:

  • Internal radiation therapy (brachytherapy or interstitial radiation therapy) - Tiny pellets (or “seeds”) that contain radioactive materials are injected into your bloodstream and guided to the hepatic artery. Tumor blood vessels are smaller than the blood vessels of healthy tissue. As a result, the seeds get stuck in the small blood cells that feed the tumors; however, they pass right through the larger blood vessels that feed healthy liver tissue. The pellets release their radiation slowly into the tumor without damaging healthy tissue. Brachytherapy lets the doctor use a higher dose of radiation than EBRT. This type of treatment involves a one-time procedure.
  • External beam radiation therapy (EBRT) - Radiation from a high-energy x-ray machine (linear accelerator) outside the body is focused on the cancer cells. EBRT can harm both the cancer cells and nearby healthy tissue. Most people are treated with EBRT for a few minutes 5 days a week for 3 to 5 weeks as an outpatient. This technique is rarely used for liver cancer.

This content has been reviewed and approved by Myo Thant, MD.

This content was last modified on August 22, 2007 .
Latest Cancer News
Multiple-agent Therapy with Metronomic Xeloda® and Nexavar® Promising for Metastatic Renal Cell Carcinoma

March 12, 2010 — Researchers from Spain have reported: “Maximum tolerated dose chemotherapy followed by metronomic chemotherapy” is a promising approach for treatment of patients with metastatic renal cell carcinoma (RCC). The details of this study were published early online in Lancet Oncology on February 16, 2010.

Complete Remission Predicts for Long Survival of Patients with Multiple Myeloma

March 12, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that achieving a complete remission (CR) was the dominant prognostic factor for long survival of patients with multiple myeloma (MM). The details of this large retrospective review were published in the March 2010 issue of Bone Marrow Transplantation.

Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer

March 12, 2010 — Researchers affiliated with the RTOG 94-08 clinical trial have reported that short-term androgen deprivation therapy (ADT) delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco on March 5-7.

Select news items provided by Reuters Health